贵州百灵（002424）(002424.SZ)12月19日晚间连续发布两则公告，公布了这家上市药企长达数年的财 务造假案调查结果及处理方案。一则为贵州百灵企业集团制药股份有限公司关于公司及相关当事人收到 《行政处罚事先告知书》的公告。经查，贵州百灵在2019年至2021年及2023年，通过不当核算销售费 用，在2019—2021年虚增利润，在2023年虚减利润，导致四年年报存在虚假记载。监管拟对公司处以 1000万元罚款；对时任董事长姜伟处以500万元罚款，并采取10年证券市场禁入措施；另有多名高管及 独立董事被处以50万至350万元不等的罚款。 另一则公告显示，因触及财务报告虚假记载的相关规定，贵州百灵股票自2025年12月23日起被实施其他 风险警示，股票简称将由"贵州百灵"变更为"ST百灵"。这意味着公司即将面临行政处罚、人员追责与资 本市场警示的三重后果。 根据贵州证监局下发的《行政处罚事先告知书》，贵州百灵涉嫌违法的核心事实在于财务核算未执行企 业会计准则，未以权责发生制为基础计提销售费用，导致利润数据严重失真。 2019年，贵州百灵少计销售费用35,012.49万元，多计利润35,012.49万元 ...

Core Viewpoint - The ongoing legal dispute involving Guizhou BaiLing, a leading traditional Chinese medicine company, may determine its ownership and control, stemming from a complex financial rescue plan and stock pledge initiated in late 2018 and early 2019, which has lasted for seven years [1][5]. Group 1: Financial Penalties and Fraud Allegations - Guizhou BaiLing and its chairman Jiang Wei, along with ten other responsible parties, were fined for financial fraud, with the company fined 10 million yuan and Jiang Wei fined 5 million yuan, along with a 10-year market ban [2]. - The Guizhou Securities Regulatory Bureau revealed that the annual reports from 2019 to 2021 and 2023 contained false records, with a total of 655 million yuan in profits inflated due to underreported sales expenses from 2019 to 2021, and a 459 million yuan profit reduction in 2023 due to overstated sales expenses [3]. Group 2: Control Dispute and Legal Proceedings - The major shareholder Jiang Wei and his associates are embroiled in a lawsuit initiated by Huachuang Securities, demanding the return of 1.761 billion yuan in loans, which includes 1.4 billion yuan in rescue funds and 361 million yuan in stock pledge financing [4]. - The court case, originally scheduled for December 3, 2025, has been postponed due to Jiang Wei's counterclaim, with no new court date announced [4]. Group 3: Stock Pledge and Financial Struggles - Huachuang Securities provided 1.4 billion yuan in funding through two asset management plans and an additional 361 million yuan in stock pledge loans, acquiring 161 million shares of Guizhou BaiLing, representing 11.54% of its total shares [7]. - The lawsuit claims that Jiang Wei's failure to fulfill his obligations could lead to a forced transfer of his pledged shares, potentially resulting in a change of control for Guizhou BaiLing [9]. Group 4: Background of the Rescue Plan - The rescue plan, initiated in December 2018, aimed to help Jiang Wei reduce stock pledge rates and ensure the stable operation of Guizhou BaiLing, with Huachuang Securities committing to provide no less than 1.8 billion yuan in rescue funds [12]. - The first phase of the rescue plan was completed in March 2019, with Huachuang Securities acquiring 74.54 million shares for 650 million yuan, and the second phase was completed in September 2019 for 750 million yuan [13]. Group 5: Impact of Stock Price Decline - Guizhou BaiLing's stock price has significantly declined from an initial 9 yuan per share to 5.63 yuan, resulting in a market capitalization drop from over 50 billion yuan to 7.9 billion yuan [33].

Core Viewpoint - Guizhou BaiLing, a leading company in the herbal medicine sector, faces significant penalties for financial fraud, including a fine of 10 million yuan for the company and 5 million yuan for its chairman, Jiang Wei, who is also banned from the market for 10 years [2][3][4]. Group 1: Financial Misconduct - The company reported false financial records in its annual reports from 2019 to 2021 and 2023, leading to a cumulative profit inflation of 655 million yuan due to underreporting sales expenses [3][4]. - In 2023, the company overstated sales expenses, resulting in a profit reduction of 459 million yuan [4]. Group 2: Control Dispute - Guizhou BaiLing is embroiled in a control dispute, with major shareholder Jiang Wei and his associates facing a lawsuit from Huachuang Securities for the return of 1.761 billion yuan in loans and interest [5][7]. - The lawsuit stems from a complex seven-year struggle related to a financial rescue plan and stock pledges initiated in late 2018 [5]. Group 3: Financial Rescue Plan - Huachuang Securities provided 1.4 billion yuan in rescue funds and 361 million yuan in stock pledge financing to Jiang Wei, acquiring a total of 11.43% of Guizhou BaiLing's shares [7][12]. - The rescue plan included multiple agreements, with fixed and floating returns based on the performance of the shares held by Huachuang Securities [13][14]. Group 4: Share Price Decline - Guizhou BaiLing's stock price has significantly declined from 9 yuan per share to 5.63 yuan, resulting in a market capitalization drop from over 50 billion yuan to 7.9 billion yuan [33]. Group 5: Corporate Governance Issues - The ongoing legal disputes and financial issues have raised concerns about the company's governance structure, with suggestions for restructuring the board to ensure balanced control [29][30].

Core Viewpoint - Guizhou BaiLing Pharmaceutical Group Co., Ltd. faces severe regulatory penalties for financial fraud involving false records in multiple annual reports from 2019 to 2021 and 2023, marking it as a significant case of financial misconduct in the A-share market [2][3]. Group 1: Regulatory Actions - On December 19, Guizhou BaiLing received an administrative penalty notice from the Guizhou Securities Regulatory Bureau, proposing a total fine of 25.6 million yuan, including 10 million yuan for the company and 5 million yuan for its chairman, Jiang Wei [2][5]. - The company is required to correct its violations and has been warned, with penalties also proposed for 10 responsible individuals totaling approximately 15.6 million yuan [5][6]. - Jiang Wei, as the chairman, is subject to a 10-year ban from the securities market due to his knowledge of the financial misconduct and failure to act [5]. Group 2: Financial Misconduct Details - Guizhou BaiLing's financial misconduct involved underreporting sales expenses by 350.12 million yuan, 240.81 million yuan, and 63.79 million yuan for the years 2019, 2020, and 2021 respectively, leading to inflated profits of the same amounts, which represented 95.73%, 115.35%, and 45.04% of the reported profit totals for those years [4]. - In 2023, the company also overstated sales expenses by 459.41 million yuan, which accounted for 93.17% of the reported profit total for that year [4]. Group 3: Investor Implications - Investors who suffered losses due to Guizhou BaiLing's financial fraud may pursue legal action for compensation, particularly those who bought shares between April 30, 2020, and November 8, 2024, and sold or held shares thereafter [7][9]. - The company's stock will be suspended for one day on December 22 and will resume trading on December 23 under a new designation "ST BaiLing," indicating financial distress [9].

中经记者 孙汝祥 夏欣 北京报道 对此，贵州证监局拟决定对贵州百灵责令改正，给予警告，并处以1000万元罚款；对时任公司董事长姜 伟，给予警告，并处以500万元罚款，同时采取10年证券市场禁入措施；对时任公司董事、总经理和董 事会秘书牛民，给予警告，并处以350万元罚款；对其他8名责任人给予警告，合计处以710万元罚款。 值得一提的是，贵州证监局拟决定的对贵州百灵1000万元罚款、姜伟500万元罚款，皆为顶格处罚。 《证券法》第一百九十七条第二款规定，信息披露义务人报送的报告或者披露的信息有虚假记载、误导 性陈述或者重大遗漏的，责令改正，给予警告，并处以100万元以上1000万元以下的罚款；对直接负责 的主管人员和其他直接责任人员给予警告，并处以50万元以上500万元以下的罚款。 贵州百灵（002424.SZ）12月19日晚间公告，公司及相关当事人收到《行政处罚事先告知书》。贵州证 监局拟对公司及10名责任人合计处以2560万元罚款。其中，拟对贵州百灵及董事长姜伟作出顶格处罚， 分别罚款1000万元、500万元。 经查，贵州百灵涉嫌违法事实为，未以权责发生制为核算基础，按收入成本费用配比原则计提销售费 用，少 ...

据红星资本局报道，12月19日，贵州百灵发布公告，公司及相关当事人已收到贵州证监局送达的《行政 处罚事先告知书》。经查，贵州百灵在2019年至2023年期间存在财务造假行为，具体表现为：2019年少 计销售费用3.5亿元，相应多计利润3.5亿元，占当期报告记载利润总额（绝对值）的95.73%；2020年少 计销售费用2.4亿元，多计利润2.4亿元，占比达115.35%；2021年少计销售费用6379.16万元，多计利润 6379.16万元，占比45.04%；2023年多计销售费用4.59亿元，少计利润4.59亿元，占比93.17%。上述财务 造假行为，导致贵州百灵披露的2019年，2020年，2021年，2023年年报存在虚假记载。 对此，贵州证监局拟对贵州百灵作出责令改正、给予警告并处以1000万元罚款的处罚。同时，对公司董 事长姜伟、总经理牛民等10名相关当事人给予警告，处以罚款合计1560万元，同时拟对姜伟采取10年证 券市场禁入措施。 与此同时，贵州百灵公告称，公司股票自2025年12月22日（星期一）开市起停牌一天，并于2025年12月 23日（星期二）开市起复牌。公司股票在2025年12月23日（ ...

【#贵州百灵3年虚增利润6.5亿被罚1000万#】#贵州百灵董事长等10人被罚合计1560万##贵州百灵3年虚 增利润6.5亿#12月19日，贵州百灵发布公告，公司及相关当事人已收到贵州证监局送达的《行政处罚事 先告知书》。经查，贵州百灵在2019年至2023年期间存在财务造假行为，具体表现为：2019年少计销售 费用3.5亿元，相应多计利润3.5亿元，占当期报告记载利润总额（绝对值）的95.73%；2020年少计销售 费用2.4亿元，多计利润2.4亿元，占比达115.35%；2021年少计销售费用6379.16万元，多计利润6379.16 万元，占比45.04%；2023年多计销售费用4.59亿元，少计利润4.59亿元，占比93.17%。上述财务造假行 为，导致贵州百灵披露的2019年，2020年，2021年，2023年年报存在虚假记载。 对此，贵州证监局拟对贵州百灵作出责令改正、给予警告并处以1000万元罚款的处罚。同时，对公司董 事长姜伟、总经理牛民等10名相关当事人给予警告，处以罚款合计1560万元，同时拟对姜伟采取10年证 券市场禁入措施。 与此同时，贵州百灵公告称，公司股票自2025年12月22日 ...

Core Viewpoint - Regulatory authorities have issued administrative penalties to four listed companies, emphasizing a strong stance against financial fraud and violations, regardless of the methods used or the amounts involved [2] Group 1: Company-Specific Violations - Far East Intelligent (ST远智) engaged in financial misconduct by using forged acceptance certificates to prematurely recognize revenue from elevator sales, resulting in inflated revenues of approximately 123 million yuan, 66.23 million yuan, and 138 million yuan from 2019 to 2021 [3][4] - Fuhua Oriental (福能东方) was involved in a scheme with its subsidiary, where it falsely recognized receivables and inflated profits by 35.8 million yuan in 2020, which accounted for 120.18% of the company's reported profit for that year [4][5] - Guizhou Bailin (贵州百灵) failed to adhere to accounting standards, leading to a misstatement of sales expenses and inflated profits by 350 million yuan in 2019 and 240 million yuan in 2020, among other discrepancies [7][8] - Bayi Steel (八一钢铁) was found to have significant non-operating fund transactions with its controlling shareholder, failing to disclose approximately 3.675 billion yuan in transfers in 2022 alone [9] Group 2: Regulatory Actions and Penalties - Far East Intelligent received a warning and a fine of 6 million yuan, with penalties imposed on its executives ranging from 200,000 to 3 million yuan [4] - Fuhua Oriental was fined 6.5 million yuan and received a warning, with its stock facing additional risk warnings due to the violations [5][6] - Guizhou Bailin faced a fine of 10 million yuan, and its chairman is subject to a 10-year ban from the securities market due to severe violations [7][8] - Bayi Steel was fined 3 million yuan, while its controlling shareholder was fined 4 million yuan for failing to disclose significant financial transactions [9]

金融市场瞬息万变，投资与经济政策深刻影响全球。我们为您带来昨夜今晨的财经新闻，涵盖股市动 态、经济数据、企业财务和政策更新，帮助您全面把握金融世界。 来源：喜娜AI 美股收盘：三大指数集体收涨 纳指涨逾1% 英伟达涨约4% 美东时间周五，美股三大指数连续第二个交易日集体收涨，纳指涨逾1%。市场受人工智能概念股走强 带动，其中英伟达、甲骨文分别上涨约4%和6.6%，后者因参与TikTok美国合资公司消息而受提振。美 光科技延续涨势，耐克则因销售前景疲软而股价重挫。热门中概股多数上涨。 核聚变成新风口，特朗普家族的眼睛又亮了 特朗普家族旗下的媒体集团（TMTG）与谷歌支持的核聚变公司TAE科技宣布合并，交易估值达60亿美 元，旨在整合资本与技术以满足AI产业激增的电力需求。合并后计划建设核聚变发电厂，目标2031年 首次发电。此举被部分议员质疑存在利益冲突，同时正值美国推动核能发展及一名顶尖核聚变科学家遇 害，引发广泛关注与猜测。 美联储拟设新账户 加密货币向支付系统再近一步 美联储提议设立新型支付账户，允许符合条件的加密货币及金融科技公司接入央行支付体系，用于清算 与结算。该账户将区别于金融机构使用的"主账户" ...

Group 1 - China Shenhua plans to issue A-shares and pay cash to acquire assets from its controlling shareholder, China Energy Group, and its wholly-owned subsidiary, West Energy, for a total transaction price of 133.598 billion yuan, with 30% paid in shares and 70% in cash [1][4] - Qingdao Port intends to invest approximately 15.7 billion yuan in two terminal projects [4] - Jifeng Co., Ltd. has been awarded a total assembly project for passenger car seats, with an estimated total lifecycle value of 9.8 billion yuan [4] Group 2 - Shengxin Lithium Energy's partner, Zhongxin Aviation, plans to purchase 200,000 tons of lithium salt products from the company between 2026 and 2030 [4] - Chlor-alkali Chemical's subsidiary plans to invest 2.975 billion yuan in an advanced materials supporting waste salt comprehensive utilization project [4] - Tianqi Lithium's third-phase chemical-grade lithium concentrate expansion project has been completed and is now in trial operation [4] Group 3 - Oriental Cable has recently won projects totaling approximately 3.125 billion yuan [4] - Jiangshan Luneng has signed a series of contracts totaling approximately 815 million yuan [4] - Huahai Wenkang has produced over 800 CMP equipment units [4] Group 4 - Sichuan Chengyu's subsidiary plans to acquire 85% of Jingyi Company for 2.409 billion yuan [4] - Qi Yi Er intends to acquire 60% of Fangzhou Technology through acquisition and capital increase [4] - Tianchuang Fashion is planning a change of control, resulting in a stock suspension [4]